Radient Pharmaceuticals and Gaur Diagno Launch Cancer Education and Public Screening Program in India to Reach 2.2 Million People

Radient Pharmaceuticals Corporation (RPC) (NYSE Amex: RPC) and its exclusive India-based distribution partner Jaiva Technologies, Inc. (JTI) and Jaiva's Indian subsidiary Gaur Diagno, Pvt Ltd (GDL) announced today it will target over 2.2 million people in potentially high cancer prone districts of northern India in phase I of its previously launched cancer education and screening program in India. Through the program GDL is actively commercializing RPC's Onko-Sure® in vitro diagnostic (IVD) cancer test with the goal of the program to drive public education; raise market awareness; and sell Onko-Sure® as a potentially life-saving cancer screening test.

The launch of GDL's cancer education and screening program in India, on behalf of RPC, includes two distinct launch strategies. The first comprises of a widespread deployment of GDL's mobile cancer screening laboratory units where Indian-based physicians and other medical staff travel to local towns to provide counseling and education, along with patient screening using RPC's Onko-Sure® IVD cancer test. The second program is focused on Company collaboration with Indian government agencies to establish GDL-sponsored cancer screening and testing facilities directly on-site in government hospitals. Physician-referred general cancer screening is being conducted at these hospitals with the goal of administering RPC's Onko-Sure® IVD cancer tests to cancer patients contacted through the program. The goal of both strategies is to reduce the incidence of cancer in India, and through each program, patients will be provided with registered health cards that will track a patient's health records for future reference and statistical analysis.

Based on response to initial program outreach, RPC now estimates test kit purchases in FY2011 to potentially reach 25,000 with revenues at an estimated US$10 million in FY2011 sales. These estimates are subject to change based on final results of the 64-point questionnaire and these figures have the potential to increase if GDL's results show more than 50% of the patients at high-risk when screened through the 64-point questionnaire.

Douglas MacLellan, Chairman and CEO of RPC, commented on the progress of the GDL's efforts on behalf of RPC, "This is a significant advance for Radient Pharmaceuticals and our FDA-approved Onko-Sure® IVD cancer test. Onko-Sure® is nicely suitable for countries that cannot invest in advanced screening products and has potential to drive significant product sales in this market alone. We look forward to continued progress on this and all parallel commercialization efforts we have in play."